PFM
KRYS icon

Privium Fund Management’s Krystal Biotech KRYS Stock Holding History

Privium Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Hold
11,170
– – 0.76% 26
2026
Q1 		$2.89M Sell
11,170
-1,000
-8% -$266K 0.6% 28
2025
Q4 		$3M Hold
12,170
– – 0.55% 28
2025
Q3 		$2.15M Buy
12,170
+2,850
+31% +$427K 0.39% 29
2025
Q2 		$1.3M Buy
9,320
+1,810
+24% +$266K 0.28% 28
2025
Q1 		$1.35M Sell
7,510
-1,740
-19% -$293K 0.35% 28
2024
Q4 		$1.45M Buy
9,250
+2,900
+46% +$514K 0.33% 29
2024
Q3 		$1.16M Sell
6,350
-70
-1% -$13.5K 0.29% 33
2024
Q2 		$1.14M Buy
6,420
+1,920
+43% +$322K 0.29% 41
2024
Q1 		$801K Sell
4,500
-2,110
-32% -$293K 0.21% 51
2023
Q4 		$826K Buy
6,610
+1,400
+27% +$155K 0.23% 48
2023
Q3 		$604K Hold
5,210
– – 0.18% 53
2023
Q2 		$603K Sell
5,210
-3,470
-40% -$354K 0.17% 54
2023
Q1 		$695K Hold
8,680
– – 0.23% 46
2022
Q4 		$694K Buy
8,680
+1,418
+20% +$105K 0.26% 42
2022
Q3 		$512K Buy
7,262
+2,782
+62% +$201K 0.19% 62
2022
Q2 		$294K Buy
4,480
+480
+12% +$29.9K 0.1% 80
2022
Q1 		$266K Buy
+4,000
New +$250K 0.06% 119

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Privium Fund Management's KRYS Position: Q2 2026 in Review

Privium Fund Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 11,170 shares worth $4.15M. The position accounts for 0.76% of the portfolio, ranked #26.

Privium Fund Management first reported a position in KRYS in Q1 2022 and has held it in 18 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Privium Fund Management held 11,170 shares of Krystal Biotech worth $4.15M as of Q2 2026.
  • Privium Fund Management left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 0.76% of Privium Fund Management's portfolio in Q2 2026, its #26 holding.
  • Privium Fund Management first reported a position in Krystal Biotech in Q1 2022 and has held it in 18 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.